A real life observational study evaluating molecular responses after switching from a standard dose twice daily Nilotinib regimen to a reduced dose once daily schedule in patients with chronic myeloid leukemia

Trial Profile

A real life observational study evaluating molecular responses after switching from a standard dose twice daily Nilotinib regimen to a reduced dose once daily schedule in patients with chronic myeloid leukemia

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms NILO-RED
  • Most Recent Events

    • 26 Dec 2017 New trial record
    • 12 Dec 2017 Results (n=67) assessing MMR 12 months after the switch to the once-daily dose-reduced nilotinib regimen presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top